DE346022T1 - Peptidfragmente von hiv. - Google Patents

Peptidfragmente von hiv.

Info

Publication number
DE346022T1
DE346022T1 DE198989305604T DE89305604T DE346022T1 DE 346022 T1 DE346022 T1 DE 346022T1 DE 198989305604 T DE198989305604 T DE 198989305604T DE 89305604 T DE89305604 T DE 89305604T DE 346022 T1 DE346022 T1 DE 346022T1
Authority
DE
Germany
Prior art keywords
isoleucine
arginine
lysine
leucine
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198989305604T
Other languages
English (en)
Inventor
Andrew James Horton-Cum-Studley Oxford Mcmichael
Douglas Fraser Headington Oxford 0X3 0Nx Nixon
Alain Robert Michael Oxford 0X2 6Jn Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE346022(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888813746A external-priority patent/GB8813746D0/en
Priority claimed from GB888815956A external-priority patent/GB8815956D0/en
Priority claimed from GB888826445A external-priority patent/GB8826445D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of DE346022T1 publication Critical patent/DE346022T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

Patentansprüche
1. Ein Peptid mit der Aminosäurenfolge eines Fragments von HIV, welches spezifisch mit einem besonderen menschlichen Leukocytantigenmolekul (HLA) der Klasse I zur Stimulierung cytotoxischer T-Lymphocytenimmunität zusammenwirkt.
2. Ein Peptid nach Anspruch 1 mit der Folge NH^-Lysin-Arginin-Tryptophan-Isoleucin-Isoleucin-Leucin-Glycin-Leucin-Asparagin-Lysin-Isoleucin-Valin-Arginin-Methionin-Tyrosin-COOH.
3. Ein Peptid nach Anspruch 1 mit der Folge NH„-Lysin-Arginin-Tryptophan-Isoleucin-Isoleucin-Leucin-Glycin-Leucin-Asparagin-Lysin-Isoleucin-Valin-Arginin-Methionin-Tyrosin-Cystein-COOH.
4. Ein Impfstoff gegen AIDS aus einem Peptid mit der Aminosäurenfolge eines Fragments von HIV, welches spezifisch mit einem besonderen menschlichen Leukocytantigenmolekul (HLA) der Klasse I zusammenwirkt.
5. Ein Impfstoff nach Anspruch 4 aus einem Peptid der Folge NH^-Lysin-Arginin-Tryptophan-Isoleucin-Isoleucin-Leucin-Glycin-Leucin-Asparagin-Lysin-Isoleucin-Valin-Arginin-Methionin-Tyrosin-COOH.
6. Ein Impfstoff nach Anspruch 4 oder 5 aus einem Peptid der Folge NH^-Lysin-Arginin-Tryptophan-Isoleucin-Isoleucin-Leucin-Glycin-Leucin-Asparagin-Lysin-Isoleucin-Valin-Arginin-Methionin-Tyrosin-Cystein-COOH.
7. Ein Impfstoff nach Anspruch 4, 5 oder 6 aus einem Peptid, welches mit HLA Al, A2, A3, B7 oder B44 zusammenwirkt, von denen jedes bei etwa 10 % der Bevölkerung zu finden ist.
8. Ein Impfstoff nach einem der Ansprüche 4 bis 7 aus einem rekombinierten Mikroorganismus, welcher so aufgebaut ist, daß er die relevante(n) Peptidfolge(n) ausdrückt.
9. Ein Verfahren zum Prüfen von Zellen auf die Anwesenheit cytotoxischer T-Lymphocyten mit Inkubieren von Zellen mit markierten B-Lymphoblastoidzellen, welche auf den HLA-Typ in Gegenwart eines Peptids nach Anspruch 1 angepaßt sind, welches mit dem relevanten HLA-Typ zusammenwirkt, und Bestimmen des Ausmasses der freigesetzten Markierung.
10. Ein Verfahren zum Behandeln eines Patienten auf AIDS oder verwandte Zustände mit Verabreichen von cytotoxischen T-Zellen, welche mit Peptid nach Anspruch 1 behandelt sind, welches mit einem im Patienten vorhandenen HLA-Molekül zusammenwirkt.
DE198989305604T 1988-06-10 1989-06-02 Peptidfragmente von hiv. Pending DE346022T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888813746A GB8813746D0 (en) 1988-06-10 1988-06-10 Peptide fragments of hiv
GB888815956A GB8815956D0 (en) 1988-07-05 1988-07-05 Peptide fragments of hiv
GB888826445A GB8826445D0 (en) 1988-11-11 1988-11-11 Peptide fragments of hiv

Publications (1)

Publication Number Publication Date
DE346022T1 true DE346022T1 (de) 1990-05-23

Family

ID=27263941

Family Applications (2)

Application Number Title Priority Date Filing Date
DE68925660T Revoked DE68925660T2 (de) 1988-06-10 1989-06-02 Peptidfragmente von HIV
DE198989305604T Pending DE346022T1 (de) 1988-06-10 1989-06-02 Peptidfragmente von hiv.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE68925660T Revoked DE68925660T2 (de) 1988-06-10 1989-06-02 Peptidfragmente von HIV

Country Status (7)

Country Link
US (2) US5459238A (de)
EP (1) EP0346022B1 (de)
JP (1) JPH0236198A (de)
AT (1) ATE134195T1 (de)
DE (2) DE68925660T2 (de)
GB (1) GB2220939B (de)
HK (1) HK141594A (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
ATE134195T1 (de) * 1988-06-10 1996-02-15 United Biomedical Inc Peptidfragmente von hiv
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments
US5336758A (en) * 1990-03-09 1994-08-09 The United States Of America As Represented By The Department Of Health And Human Services Peptides stimulating cytotoxic T cells immune to HIV RT
GB9014294D0 (en) * 1990-06-27 1990-08-15 Medical Res Council Assay for cytotoxic t cells
WO1992000098A1 (en) * 1990-06-29 1992-01-09 Daniel Zagury Methods of inducing immune response to aids virus
GB9125024D0 (en) * 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US6682731B1 (en) * 1994-03-24 2004-01-27 Ludwig Institute For Cancer Research Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
JP3693491B2 (ja) * 1997-07-11 2005-09-07 株式会社カネカ 改良された再生コラーゲン繊維及びその製造方法
DE19814701A1 (de) * 1998-04-01 1999-10-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von mit dem Gehirn assoziierten Erkrankungen, Störungen und Schädigungen
EP1225907A4 (de) * 1999-10-05 2005-06-22 Epimmune Inc Induktion zellulärer immunantworten gegen humanes immundefiziens virus-1 (hiv-1) mittels peptid- und nukleinsäureverbindungen
CA2392877C (en) * 1999-12-23 2011-11-15 Tomas Hanke Improvements in or relating to immune responses to hiv
DE10120505A1 (de) 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
EP2745845A1 (de) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Verfahren zur Vorbeugung oder Behandlung einer HIV-Infektion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
EP0201540B2 (de) * 1984-10-18 2001-10-31 Institut Pasteur Lymphadenopathie-assoziierte hüllenantigene und deren verwendungen
FR2582103B1 (fr) * 1985-03-19 1989-05-05 Canavaggio Michel Procede de determination d'une substance biologique dans un echantillon
DE3650175T3 (de) * 1985-04-29 2007-09-06 Bio-Rad Laboratories, Inc., Hercules Synthetische antigene zum nachweis von aids.
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
ES2054616T3 (es) * 1985-12-17 1994-08-16 Akzo Nv Reactivo inmunoquimico.
AU6713287A (en) * 1986-01-06 1987-07-09 F. Hoffmann-La Roche & Co. Expression of htlv-iii gag-gene
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
ZA873215B (en) * 1986-05-19 1987-10-28 Viral Technologies Inc. Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus
GB8629116D0 (en) * 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
EP0283327B1 (de) * 1987-01-16 1997-06-25 Institut Pasteur Peptide mit den immunologischen Eigenschaften von HIV-2
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
US5100777A (en) * 1987-04-27 1992-03-31 Tanox Biosystems, Inc. Antibody matrix device and method for evaluating immune status
CA1339363C (en) * 1987-05-01 1997-08-26 Alan Ray Flesher Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
AU2914889A (en) * 1987-08-28 1989-04-17 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
EP0330359A3 (de) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion
ATE134195T1 (de) * 1988-06-10 1996-02-15 United Biomedical Inc Peptidfragmente von hiv
EP0356007A3 (de) * 1988-07-22 1991-07-03 Medical Research Council Antigenische Determinanten
GB8918200D0 (en) * 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments

Also Published As

Publication number Publication date
GB2220939B (en) 1992-02-26
EP0346022B1 (de) 1996-02-14
DE68925660D1 (de) 1996-03-28
GB8912651D0 (en) 1989-07-19
US5459238A (en) 1995-10-17
US5683701A (en) 1997-11-04
GB2220939A (en) 1990-01-24
JPH0236198A (ja) 1990-02-06
DE68925660T2 (de) 1996-09-26
EP0346022A1 (de) 1989-12-13
HK141594A (en) 1994-12-23
ATE134195T1 (de) 1996-02-15

Similar Documents

Publication Publication Date Title
DE346022T1 (de) Peptidfragmente von hiv.
Giulian et al. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes.
DE68916932D1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
FI94354B (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
DE69029377T2 (de) Substituierungsanaloge von magaininpeptiden
DE69007571T2 (de) Peptidfragmente von HIV.
Niu et al. The peptide chains of some plant viruses
DE68928752T2 (de) Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
EP0466498B1 (de) Physiologisch wirksame Peptide, die eine immunoregulierende Aktivität besitzen
Jones et al. A structure-activity profile of substance P and some of its fragments on supraspinal neurones in the rat
MELDER et al. Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells
AU2254999A (en) Use of peptide T in the treatment of multiple sclerosis
ZA902831B (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p.falciparum at the sporozoite stage and in the hepatocytes
DE69124795T2 (de) Neutrophile stimulierende peptide
Knyszynski et al. Inhibition by tuftsin of Rauscher virus leukemia development in mice
DE69309269T2 (de) Monomere und dimere Peptide, ihre Verwendung zum Schutz von Zellen und ihre Herstellungsverfahren
ES2071038T3 (es) Peptidos asociados al hiv.
DE3712050A1 (de) Tripeptid mit immunostimulierender aktivitaet
RU2283663C1 (ru) Иммуномодулятор с противоопухолевой активностью и лекарственное средство на его основе
DE379516T1 (de) Hyperimmun globulin gegen hiv.
EP0545991A1 (de) Peptide, die infektionen mit menschlichem immunschwächevirus hemmen und deren anwendungsweisen
SIEMION et al. Competition between tuftsin and HBV S‐protein sequences
Oldham et al. A phase I trial of immune interferon: a preliminary report
Marx Current and Future Sources of Interferon
OLDHAM et al. A Phase I Trial of Immune Interferon